Posted on 9/6/18
Durham-based BioCryst Pharmaceuticals Has A $35M Contract with CDC
BioCryst Pharmaceuticals Inc. has received a $35 million contract with the Centers for Disease Control and Prevention, according to a Securities and Exchange Commission filing on . . .
Posted on 8/24/18
Innovate Biopharmaceuticals Enters into an Agreement with Amarex Clinical Research
RALEIGH, N.C., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and . . .
Posted on 8/16/18
Innovate Biopharma Reports Better-than-expected Loss
Drug development company Innovate Biopharmaceuticals Inc. reported a second quarter loss that beat analyst estimates.The Raleigh-based company reported a net loss of $4.2 million, or 16 . . .
Posted on 8/14/18
Heat Biologics Reports Larger Loss on Higher R&D Expenses
Drug development company Heat Biologics Inc. reported a larger-than-expected second quarter loss due to higher research and development expenses.The Durham-based company reported a loss of $4.1 . . .
Posted on 8/10/18
Durham-based Aerie Pharma Reports Larger-than-expected Loss
Aerie Pharmaceuticals Inc., which specializes in eye treatments, reported a larger-than-expected second quarter loss due to higher expenses, but sales of its key drug were strong.The . . .
Posted on 8/8/18
G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today provided an update on its corporate activities, . . .
Posted on 8/8/18
Novan Provides Business Update
MORRISVILLE, N.C., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (Nasdaq:NOVN) today provided a comprehensive business update in its Form 10-Q for the second quarter of . . .
Posted on 8/7/18
Syneos Health Announces Pricing of Secondary Offering of Common Stock
RALEIGH, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO . . .
Posted on 8/7/18
Syneos Health Announces Secondary Offering of Common Stock
RALEIGH, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO . . .
Posted on 8/7/18
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 10,454,546 . . .
Posted on 8/5/18
DLA Piper Advises Liquidia Technologies in its $50M IPO
DLA Piper advised Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company, in its US$50 million initial public offering. The company is focused on the . . .
Posted on 8/5/18
vTv Therapeutics Announces Second Quarter 2018 Results and Update
HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent . . .
Posted on 8/2/18
Syneos Health Rises 7.5 Percent After Earnings Beat Expectations
Syneos Health Inc., which tests and develops drugs for other companies, reported second-quarter earnings slightly above analyst expectations, sending its stock price up more than 7 . . .
Posted on 8/2/18
Syneos Health Reports Second Quarter 2018 Results
RALEIGH, N.C., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract . . .
Posted on 8/2/18
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 9,090,910 . . .
Posted on 8/2/18
BioCryst Pharmaceuticals Commences Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) a biotechnology company focused on the development and commercialization of treatments . . .
Posted on 7/24/18
Struggling Argos Therapeutics Gives Retention Pay To Executives
Struggling Argos Therapeutics Inc. has agreed to give its three top executives retention pay during the next month as a way of keeping them on board . . .
Posted on 7/23/18
Bioventus Enters Into Definitive Agreement to Divest BMP Development Program to Viscogliosi Brothers
DURHAM, N.C.--(BUSINESS WIRE)--Bioventus, a global leader in orthobiologic solutions, has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program . . .
Posted on 7/11/18
Bioasis and BioAgilytix Announce Strategic Collaboration
RICHMOND, British Columbia & GUILFORD, Conn. & DURHAM, N.C.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the . . .
Posted on 6/25/18
BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements
RESEARCH TRIANGLE PARK, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare . . .
Posted on 6/18/18
New Study Finds Reusable Bronchoscopes Contaminated and Damaged Even When Proper Cleaning and Disinfection Steps are Taken
Using Single-Use Bronchoscopes Could Significantly Reduce the Risk of Life-threatening Infection Transmission Among PatientsBronchoscopy is one of the most common interventional pulmonology procedures and most practitioners . . .
Posted on 6/12/18
Aura Biosciences Earns CEO Cancer Gold Standard Accreditation
CARY, N.C.--(BUSINESS WIRE)--The CEO Roundtable on Cancerhas accredited Aura Biosciences of Cambridge, MA — a biotechnology company developing a new class of therapies to target and . . .
Posted on 6/11/18
Fennec Pharmaceuticals Set to Join Russell 3000 Index
RESEARCH TRIANGLE PARK, N.C., June 11, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a . . .
Posted on 6/3/18
Novan Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MORRISVILLE, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today reported that the Compensation Committee of Novan’s Board of Directors . . .
Posted on 5/22/18
PPD, Evidera Join NEWDIGS Initiative at MIT as a Strategic Partner
WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD), and its real-world research and market access business unit, Evidera, have joined the Massachusetts Institute of Technology Center for . . .
Charlotte Raleigh
